Overview

Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification in Patients With Poorly Controlled Type 2 Diabetes

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

Despite advances in diabetes management, many T2DM patients in China fail to achieve optimal glycemic control. One of the possible reasons is associated with the delay in therapeutic decision making that lags behind glycemic rise. We design this study and presume that using vildagliptin and metformin in combination with basal insulin as sequential treatment after intensive insulin therapy, might better modulate the dual islet hormone dysfunction than traditionally stepwise upgrading therapy pattern in patients with poorly controlled T2DM, and thus lead to a glucose normalization, β-cell function improvement and therapy simplification.

Phase:

Phase 4

Details

Lead Sponsor:

Yanbing Li

Treatments:

Insulin
Metformin
Vildagliptin